Takeda Pharmaceutical Company LimitedTAK

Where TAK's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$18.26+0.15 (+0.83%)Previous close
NYSEHealthcare

TAK Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
TAK Net Debt / EBITDA historyTAK Net Debt / EBITDA from Sep 2023 to Jun 2026: low 3.02, high 4.27, latest 3.53.2.913.283.644.014.37Sep 23Mar 24Sep 24Jun 25Dec 25Jun 26med 3.53

TAK Net Debt / EBITDA by year

Yearly range of TAK’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from 0.8 to 11.1, averaging 4.0.

TAK Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
20263.13.33.53.5
20253.03.43.63.0
20243.33.84.23.6
20233.23.74.34.3
20223.13.53.93.1
20213.13.43.73.2
20204.96.07.04.9
20197.08.911.17.0
20181.73.16.56.5
20171.61.82.31.6
20160.81.01.11.1

Get notified when TAK Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.